Share:

RARC Researchers Receive New NIDA Grants

Congratulations to RARC Chair of Treatment & Recovery, Dr. Nina Cooperman, on her two new R01 awards from NIDA:

9/30/22-9/29/27
R01DA057631
Motivational Interviewing and Mindfulness-Oriented Recovery Enhancement for Tobacco Dependence and Other Drug use in Methadone Treatment
$3,361,632
Major Goals: The major goal of this proposal is to conduct a Hybrid Type 2 implementation-effectiveness study of mindfulness-oriented recovery enhancement and motivational interviewing as an adjunct to methadone treatment for tobacco and other drug use.


9/30/22-7/31/27
R01DA056537
Implementation and Effectiveness of Mindfulness-Oriented Recovery Enhancement as an Adjunct to Methadone Treatment for Opioid Use Disorder
$3,900,536
Major Goals: The major goal of this proposal is to conduct a Hybrid Type 2 implementation-effectiveness study of mindfulness-oriented recovery enhancement as an adjunct to methadone treatment for opioid use disorder and chronic pain.

Congratulations to RARC Researcher, Dr. Tanya Saraiya, on her new K23 Clinical Trial award from NIDA:

9/15/22-8/31/23
K23DA055209
Integrated Treatment for Co-Occurring Opioid Use Disorder and Posttraumatic Stress Disorder
$200,651
This project will test whether augmenting medications for opioid use disorder (OUD) with an adapted, trauma-focused, integrated behavioral treatment for substance use disorders and co-occurring PTSD (i.e., Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure; COPE) will enhance clinical outcomes.